AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The considerable mortality and morbidity associated with atrial fibrillation (AF) pose a
substantial burden on patients and health care services. Although the management of AF …

Background Atrial fibrillation is a chronic, progressive disorder, and persistent forms of atrial
fibrillation are associated with increased risks of thromboembolism and heart failure …

Background: The inspIRE study (Study for Treatment of Paroxysmal Atrial Fibrillation [PAF]
by Pulsed Field Ablation [PFA] System With Irreversible Electroporation [IRE]) evaluated …

Aims Clinical practice guidelines restrict rhythm control therapy to patients with symptomatic
atrial fibrillation (AF). The EAST-AFNET 4 trial demonstrated that early, systematic rhythm …

Despite marked progress in the management of atrial fibrillation (AF), detecting AF remains
difficult and AF-related complications cause unacceptable morbidity and mortality even on …

Aims Treatment guidelines for patients with atrial fibrillation (AF) suggest that patients should
be managed with an antiarrhythmic drug (AAD) before undergoing catheter ablation (CA) …

Importance Early rhythm control of atrial fibrillation (AF) with either antiarrhythmic drugs
(AADs) or catheter ablation has been reported to improve cardiovascular outcomes …

Introduction Stroke is one of the leading causes of mortality and morbidity globally. Atrial
fibrillation (AF) is the most common sustained cardiac arrhythmia. It is set to reach epidemic …